1. 1.Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788. [DOI:10.1371/journal.pone.0249788] [PMID] []

2. Alnajashi H, Jabbad R. Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. PLoS One. 2020;15(10):e0241103. [DOI:10.1371/journal.pone.0241103] [PMID] []

3. Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275-301. [DOI:10.1042/EBC20160017] [PMID] []

4. Jungen MJ, Ter Meulen BC, van Osch T, Weinstein HC, Ostelo R. Inflammatory biomarkers in patients with sciatica: a systematic review. BMC Musculoskelet Disord. 2019;20(1):156. [DOI:10.1186/s12891-019-2541-0] [PMID] []

5. Yalachkov Y, Anschuetz V, Jakob J, Schaller-Paule MA, Schaefer JH, Reilaender A, et al. C-Reactive Protein Levels and Gadolinium-Enhancing Lesions Are Associated With the Degree of Depressive Symptoms in Newly Diagnosed Multiple Sclerosis. Front Neurol. 2021;12:719088. [DOI:10.3389/fneur.2021.719088] [PMID] []

6. Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021;11(1):464. [DOI:10.1038/s41598-020-79431-7] [PMID] []

7. Fahmi RM, Ramadan BM, Salah H, Elsaid AF, Shehta N. Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2021;51. [DOI:10.1016/j.msard.2021.102921] [PMID]

8. Toori KU, Qureshi MA, Chaudhry A, Safdar MF. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. Pak J Med Sci 2021;37(5):1435-9. [DOI:10.12669/pjms.37.5.4194] [PMID] []

9. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014;194:145-58. [DOI:10.1016/j.virusres.2014.09.011] [PMID] []

10. Taherifard E, Taherifard E. Neurological complications of COVID-19: a systematic review. Neurol Res. 2020;42(11):905-12. [DOI:10.1080/01616412.2020.1796405] [PMID]

11. Neema M, Stankiewicz J, Arora A, Guss ZD, Bakshi R. MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics. 2007;4(4):602-17. [DOI:10.1016/j.nurt.2007.08.001] [PMID] []

12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. [DOI:10.1002/ana.22366] [PMID] []

13. Naghavi S, Kavosh A, Adibi I, Shaygannejad V, Arabi S, Rahimi M, et al. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. Mult Scler Relat Disord. 2022;57:103335. [DOI:10.1016/j.msard.2021.103335] [PMID] []

14. Lima M, Aloizou AM, Siokas V, Bakirtzis C, Liampas I, Tsouris Z, et al. Coronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia? Rev Neurosci. 2022;33(7):703-20. [DOI:10.1515/revneuro-2021-0148] [PMID]

15. Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol. 2020;27(9):1764-73. [DOI:10.1111/ene.14277] [PMID] []

16. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206-9. [DOI:10.1021/acschemneuro.0c00201] [PMID]

17. Alter TH, Helbig T, Chiappetta G. Case report: Multiple sclerosis diagnosis after anterior lumbar interbody fusion and presumed COVID-19 infection. Surg Neurol Int. 2022;13:125. [DOI:10.25259/SNI_192_2022] [PMID] []

18. Jeon YH, Choi S, Park JH, Lee JK, Yeo NS, Lee S, et al. Sudden Death Associated With Possible Flare-Ups of Multiple Sclerosis After COVID-19 Vaccination and Infection: A Case Report and Literature Review. J Korean Med Sci. 2023;38(10):e78. [DOI:10.3346/jkms.2023.38.e78] [PMID] []

19. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol. 2007;79:357-75. [DOI:10.1016/S0074-7742(07)79016-5] [PMID]

20. Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13:128. [DOI:10.1186/1471-2377-13-128] [PMID] []

21. Libbey JE, Fujinami RS. Viral mouse models used to study multiple sclerosis: past and present. Arch Virol. 2021;166(4):1015-33. [DOI:10.1007/s00705-021-04968-5] [PMID] []

22. Peker BO, Sener AG, Kaptan Aydogmus F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J Immunol Methods. 2021;499:113174. [DOI:10.1016/j.jim.2021.113174] [PMID] []

23. Taeschler P, Cervia C, Zurbuchen Y, Hasler S, Pou C, Tan Zea. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy. 2022;77(8):2415-30. [DOI:10.1111/all.15302] [PMID] []

24. Mejdoub S, Feki S, Farhat N, Dammak M, Hachicha H, Sakka S, et al. Antinuclear antibodies positivity is not rare during multiple sclerosis and is associated with relapsing status and IgG oligoclonal bands positivity. Rev Neurol (Paris). 2022;178(8):812-6. [DOI:10.1016/j.neurol.2021.11.016] [PMID]

25. Alnajashi H, Alshamrani F. Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2021;5:2021. [DOI:10.1186/s41983-021-00284-6]

26. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-4. [DOI:10.1016/j.medmal.2020.03.007] [PMID] []

27. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420-9. [DOI:10.1093/ije/dyab012] [PMID] []

28. Moosazadeh M, Nabinezhad-Male F, Afshari M, Nasehi MM, Shabani M, Kheradmand M, et al. Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis. AIMS Neurosci. 2021;8(2):239-53. [DOI:10.3934/Neuroscience.2021013] [PMID] []

29. Ismailova A, White JH. Vitamin D, infections and immunity. Rev Endocr Metab Disord. 2022;23(2):265-77. [DOI:10.1007/s11154-021-09679-5] [PMID] []

30. Nurshad A. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409-11. [DOI:10.1002/jmv.26097] [PMID] []

31. Ji AL, Liu ZH, Chen WW, Huang WJ. The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period. Eur Rev Med Pharmacol Sci. 2016;20(20):4274-6.

32. Nazeri M, Bazrafshan H, Abolhasani Foroughi A. Serum inflammatory markers in patients with multiple sclerosis and their association with clinical manifestations and MRI findings. Acta Neurol Belg. 2022;122(5):1187-93. [DOI:10.1007/s13760-021-01647-9] [PMID]

33. M.M. E, Al-Kaisy M, Regeia WAL, Khan HJ. The Prognostic Accuracy of Neutrophil -Lymphocyte Ratio in COVID-19 Patients. Front Emerg Med. 2021;5(1):e8.

34. Wu L, Zou S, Wang C, Tan X, Yu M. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in Chinese Han population from Chaoshan region in South China. BMC Cardiovasc Disord. 2019;19(1):125. https://doi.org/10.1186/s12872-022-02563-3 [DOI:10.1186/s12872-019-1110-7]

35. Huang WC, Lin HC, Yang YH, Hsu CW, Chen NC, Tsai WC, et al. Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;58:103514. [DOI:10.1016/j.msard.2022.103514] [PMID]